Published in Cancer Biol Ther on March 16, 2007
Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers | NCT00617916
Precise Recognition With Enhanced Vision of Endocrine Neck Targets (PREVENT) | NCT04745793
Medical hyperspectral imaging: a review. J Biomed Opt (2014) 2.07
Hyperspectral imaging and quantitative analysis for prostate cancer detection. J Biomed Opt (2012) 1.44
Spectral-spatial classification for noninvasive cancer detection using hyperspectral imaging. J Biomed Opt (2014) 1.28
Hyperspectral Imaging for Cancer Surgical Margin Delineation: Registration of Hyperspectral and Histological Images. Proc SPIE Int Soc Opt Eng (2014) 1.26
Framework for hyperspectral image processing and quantification for cancer detection during animal tumor surgery. J Biomed Opt (2015) 1.05
Tongue tumor detection in medical hyperspectral images. Sensors (Basel) (2011) 1.03
A Minimum Spanning Forest-Based Method for Noninvasive Cancer Detection With Hyperspectral Imaging. IEEE Trans Biomed Eng (2015) 0.95
Scanning, non-contact, hybrid broadband diffuse optical spectroscopy and diffuse correlation spectroscopy system. Biomed Opt Express (2016) 0.77
HYPERSPECTRAL AUTOFLUORESCENCE IMAGING OF DRUSEN AND RETINAL PIGMENT EPITHELIUM IN DONOR EYES WITH AGE-RELATED MACULAR DEGENERATION. Retina (2016) 0.75
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res (2003) 4.15
Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med (2013) 3.51
The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst (2008) 3.40
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol (2006) 2.55
Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. Am J Gastroenterol (2010) 2.44
Fetal hemoglobin in sickle cell anemia. Blood (2011) 2.44
The clinical significance of serrated polyps. Am J Gastroenterol (2010) 2.21
Sertoli cells from non-obstructive azoospermia and obstructive azoospermia patients show distinct morphology, Raman spectrum and biochemical phenotype. Hum Reprod (2013) 2.06
A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen. Clin Trials (2011) 1.91
Topical tretinoin therapy and all-cause mortality. Arch Dermatol (2009) 1.85
Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res (2006) 1.64
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res (2007) 1.56
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Measuring clinically important changes with patient-oriented questionnaires. Med Care (2002) 1.50
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
Retracted HIC1 regulates tumor cell responses to endocrine therapies. Mol Endocrinol (2009) 1.42
Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J (2005) 1.38
Bone morphogenetic protein signaling regulates the size of hair follicles and modulates the expression of cell cycle-associated genes. Proc Natl Acad Sci U S A (2006) 1.35
Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J (2002) 1.34
Observational methods in comparative effectiveness research. Am J Med (2010) 1.33
Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol (2004) 1.30
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J (2004) 1.29
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood (2002) 1.26
Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. Am J Hematol (2011) 1.26
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Sun protection policies and environmental features in US elementary schools. Arch Dermatol (2002) 1.23
Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. Am J Gastroenterol (2004) 1.20
Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res (2011) 1.15
Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NCoR repressor complex. Blood (2006) 1.15
Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. Clin J Am Soc Nephrol (2013) 1.12
The use of medical hyperspectral technology to evaluate microcirculatory changes in diabetic foot ulcers and to predict clinical outcomes. Diabetes Care (2007) 1.12
Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis (2008) 1.12
Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets (2003) 1.10
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood (2011) 1.09
Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer (2009) 1.08
Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem (2006) 1.08
Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem (2002) 1.05
Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med (2002) 1.04
Protein kinase C delta is required for survival of cells expressing activated p21RAS. J Biol Chem (2007) 1.04
Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive. Cell Growth Differ (2002) 1.03
Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis (2005) 1.03
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol (2012) 1.02
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res (2007) 1.02
SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate (2012) 1.00
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res (2003) 0.98
The safety assessment of fragrance materials. Regul Toxicol Pharmacol (2003) 0.98
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors. Endocr Relat Cancer (2011) 0.97
Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci (2010) 0.95
Hyperspectral imaging: a new approach to the diagnosis of hemorrhagic shock. J Trauma (2006) 0.94
Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol (2009) 0.94
Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol (2009) 0.93
Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics (2008) 0.93
Generation of male germ cells from induced pluripotent stem cells (iPS cells): an in vitro and in vivo study. Asian J Androl (2012) 0.92
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology (2002) 0.91
Drosophila female sterile (1) homeotic is a multifunctional transcriptional regulator that is modulated by Ras signaling. Dev Dyn (2008) 0.91
Association of XRCC3 Thr241Met polymorphisms and gliomas risk: evidence from a meta-analysis. Asian Pac J Cancer Prev (2013) 0.91
Coffee consumption and prostate cancer risk: an updated meta-analysis. Cancer Causes Control (2014) 0.91
Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett (2007) 0.91
Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Anticancer Drugs (2008) 0.90
Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther (2007) 0.90
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol (2005) 0.90
An evaluation of statistical approaches for analyzing physician-randomized quality improvement interventions. Contemp Clin Trials (2008) 0.90
Butyrate histone deacetylase inhibitors. Biores Open Access (2012) 0.90
T-oligos inhibit growth and induce apoptosis in human ovarian cancer cells. Oligonucleotides (2011) 0.89
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies. Adv Virol (2012) 0.89
Colorectal serrated pathway cancers and precursors. Histopathology (2014) 0.89
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1. Cell Signal (2008) 0.89
Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. Mod Pathol (2011) 0.88
Comparison between the effects of normoxia and hypoxia on antioxidant enzymes and glutathione redox state in ex vivo culture of CD34(+) cells. Comp Biochem Physiol B Biochem Mol Biol (2008) 0.87
Direct transdifferentiation of spermatogonial stem cells to morphological, phenotypic and functional hepatocyte-like cells via the ERK1/2 and Smad2/3 signaling pathways and the inactivation of cyclin A, cyclin B and cyclin E. Cell Commun Signal (2013) 0.87
Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J Cell Physiol (2003) 0.87
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. Br J Haematol (2010) 0.87
Systemic effects of shock and resuscitation monitored by visible hyperspectral imaging. Diabetes Technol Ther (2003) 0.86
Identification of novel small-molecule inducers of fetal hemoglobin using pharmacophore and 'PSEUDO' receptor models. Chem Biol Drug Des (2006) 0.86
Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells. J Cell Physiol (2012) 0.86
Novel therapeutic candidates, identified by molecular modeling, induce γ-globin gene expression in vivo. Blood Cells Mol Dis (2011) 0.85
Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. J Nerv Ment Dis (2014) 0.85
The association of interleukin-16 gene polymorphisms with IL-16 serum levels and risk of nasopharyngeal carcinoma in a Chinese population. Tumour Biol (2013) 0.85
Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol (2010) 0.85
Aberrant gene expression profiles in pluripotent stem cells induced from fibroblasts of a Klinefelter syndrome patient. J Biol Chem (2012) 0.85
Nanoproteomic analysis of extracellular receptor kinase-1/2 post-translational activation in microdissected human hyperplastic colon lesions. Proteomics (2013) 0.84
Mutations that abrogate transactivational activity of the feline leukemia virus long terminal repeat do not affect virus replication. Virology (2003) 0.84
Differentiation of induced pluripotent stem cells into male germ cells in vitro through embryoid body formation and retinoic acid or testosterone induction. Biomed Res Int (2012) 0.83
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) (2010) 0.83
Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. J Cell Biochem (2005) 0.83
Generation, characterization, and potential therapeutic applications of cardiomyocytes from various stem cells. Stem Cells Dev (2012) 0.83
Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism. Virology (2005) 0.83
Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. Pathol Oncol Res (2015) 0.82
Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis (2006) 0.82
A SAS macro for a clustered permutation test. Comput Methods Programs Biomed (2009) 0.82